Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28712083 | 0.98 | LTB4R2 (0.63) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL4924149 | 0.98 | LTB4R2 (0.63) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL29450616 | 0.98 | LTB4R2 (0.63) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL4330338 | 0.95 | LTB4R2 (0.70) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL28217434 | 0.92 | LMNA (0.68) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL27357692 | 0.92 | LTB4R2 (0.56) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL3455343 | 0.91 | LTB4R2 (0.60) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL7129964 | 0.91 | ALOX5 (0.66) | LTB4R2LMNANPC1ALOX15TSHR | |
| SCHEMBL7238328 | 0.90 | EPHX2 (0.60) | LTB4R2LMNAALOX15HSD17B10CNR2 | |
| SCHEMBL4156966 | 0.89 | LTB4R2 (0.54) | LTB4R2LMNANPC1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1079792-C | DP-IV-serine protease inhibitors | FERRING BV (NL) | 2002-02-27 | — | — | CN | claimed |
| CN-1141033-A | Enzyme inhibitors | FERRING BV (NL) | 1997-01-22 | — | — | CN | claimed |
| US-9738685-B2 | Use of ruthenium complexes for preparing amides, polypeptides and cyclic dipeptides | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-22 | — | — | US | disclosed |
| US-9738685-B2 | Use of ruthenium complexes for preparing amides, polypeptides and cyclic dipeptides | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-22 | — | — | US | disclosed |
| US-20160152663-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-06-02 | — | — | US | disclosed |
| US-20160152663-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-06-02 | — | — | US | disclosed |
| US-9290441-B2 | Use of ruthenium complexes for formation and/or hydrogenation of amides and related carboxylic acid derivatives | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-22 | — | — | US | disclosed |
| US-9290441-B2 | Use of ruthenium complexes for formation and/or hydrogenation of amides and related carboxylic acid derivatives | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-22 | — | — | US | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| US-8178723-B2 | Process for preparing amides from alcohols and amines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-8178723-B2 | Process for preparing amides from alcohols and amines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-04-30 | — | — | US | disclosed |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | ADH5, ADH1C, ADH1A | LTB4R2 2354/4885LMNA 2176/4885NPC1 4444/4885 |
| US-20090112005-A1 | PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES | ADH1A, ADH5, ADH1C | LTB4R2 1537/4885LMNA 1682/4885NPC1 3922/4885 |
| US-20160152663-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | ADH5, ADH1C, ADH1A | LTB4R2 2354/4885LMNA 2176/4885NPC1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.